A Study to Evaluate Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2390g - Tabular View

Tracking Information
First Received Date ^ICMJE	April 26, 2005
Last Updated Date	June 23, 2005
Start Date ^ICMJE
Primary Completion Date
Current Primary Outcome Measures ^ICMJE
Original Primary Outcome Measures ^ICMJE
Change History	Complete list of historical versions of study NCT00109252 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ^ICMJE
Original Secondary Outcome Measures ^ICMJE

Descriptive Information
Brief Title ^ICMJE	A Study to Evaluate Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2390g
Official Title ^ICMJE	An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of 1.0 Mg/Kg Subcutaneously Administered Efalizumab Followed by Efalizumab Taper in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2390g
Brief Summary	This is an open-label, multicenter study designed to evaluate the efficacy and safety of efalizumab administered at weekly SC (subcutaneous) doses of 1.0 mg/kg followed by efalizumab taper in subjects with plaque psoriasis who previously participated in Study ACD2390g.
Detailed Description
Study Phase	Phase III
Study Type ^ICMJE	Interventional
Study Design ^ICMJE	Treatment, Open Label
Condition ^ICMJE	Psoriasis
Intervention ^ICMJE	Drug: Raptiva (efalizumab)
Study Arms / Comparison Groups
Publications *
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Completed
Enrollment ^ICMJE	0
Completion Date
Primary Completion Date
Eligibility Criteria ^ICMJE	Inclusion Criteria: Signed informed consent Previous participation in Study ACD2390g For women of childbearing potential, continued use of an acceptable method of contraception for the duration of their participation in the study Willingness to continue to hold sun exposure reasonably constant and to avoid use of tanning booths or other UV light sources throughout the study Exclusion Criteria: Any medical condition that, in the judgment of the investigator, would jeopardize the subject’s safety following exposure to efalizumab Systemic therapy for psoriasis (ET Day 0 through FU Day 84 or upon relapse or unusual presentation of psoriasis in the FU period, whichever occurs first) Systemic immunosuppressive drugs for other indications (ET Day 0 through FU Day 84) Topical therapies for psoriasis (ET Day 0 through ET Day 84) Live virus or bacteria vaccines (ET Day 0 through FU Day 84) Other vaccines or allergy desensitization (it is recommended that these be scheduled after FU Day 84) Other experimental drugs or treatments (ET Day 0 through FU Day 84) Beta-Blockers, ACE inhibitors, interferons, quinidine, antimalarial drugs, or lithium (if clinically indicated, such medications are allowed but the dosage should be held constant between ET Day 0 and TT Day 84)
Gender	Both
Ages
Accepts Healthy Volunteers	No
Contacts ^ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ^ICMJE

Administrative Information
NCT ID ^ICMJE	NCT00109252
Responsible Party
Study ID Numbers ^ICMJE	ACD2391g
Study Sponsor ^ICMJE	Genentech
Collaborators ^ICMJE
Investigators ^ICMJE
Information Provided By	Genentech
Verification Date	April 2005
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP